









Markets
/
Stocks
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

View Detailed Chart

5.640USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

517.70MMarket Cap

LossP/E TTM



Verrica Pharmaceuticals Inc

5.640

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+0.18%

5 Days

-14.67%

1 Month

+698.08%

6 Months

+779.74%

Year to Date

+705.71%

1 Year

-2.93%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts

BUY

Current Rating

40.000

Target Price

609.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Verrica Pharmaceuticals Inc

VRCA

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(2)

Buy(9)

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

1.005

Buy

RSI(14)

79.178

Buy

STOCH(KDJ)(9,3,3)

78.141

Neutral

ATR(14)

0.727

High Vlolatility

CCI(14)

61.642

Neutral

Williams %R

23.005

Buy

TRIX(12,20)

15.582

Buy

StochRSI(14)

0.218

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

6.058

Sell

MA10

3.980

Buy

MA20

2.405

Buy

MA50

1.319

Buy

MA100

0.916

Buy

MA200

0.904

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Ticker SymbolVRCA

CompanyVerrica Pharmaceuticals Inc

CEODr. Jayson Rieger

Websitehttps://verrica.com/